Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
James Xue
|
| gptkbp:collaboratesWith |
gptkb:AveXis
gptkb:WuXi_Biologics Mirum Pharmaceuticals |
| gptkbp:country |
gptkb:China
|
| gptkbp:focusesOn |
oncology
genetic diseases rare diseases |
| gptkbp:foundedBy |
James Xue
|
| gptkbp:foundedYear |
2012
|
| gptkbp:headquartersLocation |
gptkb:Beijing,_China
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:Hong_Kong_Stock_Exchange
|
| gptkbp:notableProduct |
CAN008
CAN108 (maralixibat) |
| gptkbp:stockExchange |
gptkb:Hong_Kong_Stock_Exchange
|
| gptkbp:stockSymbol |
1228.HK
|
| gptkbp:website |
https://www.canbridgepharma.com/
|
| gptkbp:bfsParent |
gptkb:Lilly_Asia_Ventures
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
CANbridge Pharmaceuticals
|